XM tidak memberikan layanan kepada penduduk Amerika Serikat.

Activist AREX Capital wins one seat in proxy fight at Enhabit



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 2-Activist AREX Capital wins one seat in proxy fight at Enhabit</title></head><body>

Changes sourcing in lead, adds new details throughout

By Svea Herbst-Bayliss

July 25 (Reuters) - Enhabit EHAB.N investors elected one of AREX Capital Management's director nominees after the activist investor called on them to replace seven of the home health and hospice provider's directors to help improve financial performance.

Enhabit said on Thursday shareholders added Mark Ohlendorf to the board and re-elected eight of the company's nine legacy directors, including the chief executive officer and two directors who joined last year when Enhabit reached an agreement with another activist investor.

Reuters first reported AREX won one seat and that Ohlendorf, who has experience as a public company chief financial officer, was chosen. He will replace Susan LaMonica who joined Enhabit's board as an independent director in 2022.

Enhabit's fight with AREX is one of only a handful of activist investors' campaigns to have made it to a vote this year, underscoring many investors' and companies' preference to reach agreements for board seats and other concessions before shareholders weigh in.

While Enhabit has many hedge fund investors who were thought to back AREX, it also counts the three main index funds - BlackRock BLK.N, Vanguard and State Street STT.N - as big shareholders. In this vote those three sided with management's candidates, sources familiar with the preliminary vote tally said.

These investors ignored the recommendations of proxy advisory firms Institutional Shareholder Services (ISS) and Glass Lewis who had urged investors to elect three AREX nominees, arguing the company needed more expertise in the home health and hospice business and public company financial reporting.

Enhabit's share price has tumbled roughly 60% since it was spun off of post-acute healthcare services provider Encompass Health EHC.N in July 2022. It climbed nearly 10% in the last five days and was up nearly 4% in midday trading on Thursday.

AREX, which owns a 4.9% stake in Enhabit, urged management last year to immediately start a strategic review. Enhabit in May decided to continue as an independent company and urged investors to stick with its directors now, arguing big changes could jeopardize recent improvements.

In 2023, the company reached a settlement with Cruiser Capital and Harbour Point Capital Management and appointed two new directors to the board.





Reporting by Svea Herbst-Bayliss
Editing by Chris Reese

</body></html>

Pengungkapan: Entitas XM Group menyediakan layanan khusus eksekusi dan akses ke Fasilitas Trading Online kami, yang memungkinkan Anda untuk melihat dan/atau menggunakan konten yang tersedia pada atau melalui situs, yang tidak untuk mengubah atau memperluas, serta tidak mengubah atau memperluas hal tersebut. Akses dan penggunaan ini selalu sesuai dengan: (i) Syarat dan Ketentuan; (ii) Peringatan Risiko; dan (iii) Pengungkapan Penuh. Oleh karena itu, konten disediakan hanya sebagai informasi umum. Anda juga harus ketahui bahwa konten Fasilitas Trading Online kami bukan sebagai ajakan atau tawaran untuk untuk melakukan transaksi apa pun di pasar finansial. Trading di pasar finansial mana pun melibatkan tingkat risiko yang signifikan pada modal Anda.

Semua materi yang diterbitkan di Fasilitas Trading Online kami hanya untuk tujuan edukasi/informasi dan tidak boleh mengandung nasihat dan rekomendasi finansial, pajak investasi atau trading, catatan harga trading kami, penawaran, permintaan, transaksi dalam instrumen finansial apa pun atau promo finansial untuk Anda yang tidak diminta.

Konten pihak ketiga apa pun, serta konten yang disiapkan oleh XM, seperti opini, berita, riset, analisis, harga, informasi lain atau link ke situs pihak ketiga yang tersedia "sebagaimana adanya", sebagai komentar pasar umum dan bukan menjadi nasihat investasi. Sejauh konten apa pun ditafsirkan sebagai penelitian investasi, Anda harus memperhatikan dan menerima bahwa konten tersebut tidak dimaksudkan dan belum disiapkan sesuai dengan persyaratan hukum yang dirancang untuk mempromosikan kemandirian riset investasi dan dengan demikian akan dianggap sebagai komunikasi pemasaran di bawah hukum dan peraturan yang relevan. Mohon dipastikan bahwa Anda telah membaca dan memahami Notifikasi pada Riset Investasi Non-Independen dan Peringatan Risiko kami mengenai informasi di atas, yang dapat diakses disini.

Peringatan Resiko: Modal Anda beresiko. Produk dengan leverage mungkin tidak cocok bagi semua orang. Silahkan pertimbangkan Pengungkapan Resiko kami.